Vanela Bushi

TimelyAI is building a Marketing Saas for Time-based Businesses. “The idea is to solve the most burning need of our customers- Growing their clientele at an affordable price and being able to build lasting relationships with them for repeat business and referrals.” "Coming soon with something extremely crazy!"

CCX empowers you to plan, negotiate, and administer deals on your terms, with a simple and configurable infrastructure. Our proven technology delivers your strategy, and better outcomes.

Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development.

Valink Therapeutics focusses on synergistic and non-obvious target combinations to create novel multivalent bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications. Valink is a platform therapeutics company focussing on the discovery of bsADCs based out of Cambridge, MA and London, UK. The company is a VC-backed & Y Combinator (W21)-incubated spin-out of the University of Oxford, with over $20M total capital raised.

We are facing a global crisis where bacterial infections are becoming increasingly deadly due to antibiotic resistance. The health and economic consequences are staggering, with bacterial disease predicted to be the #1 cause of death by 2050. Alternatives are urgently needed, but nature already has its solution: phages, the natural predators of bacteria. At Phagos, we are bringing back phage technology by combining advances in microbiology with cutting-edge artificial intelligence. Our patented technology makes large-scale, customized phage-based veterinary medicines possible for the first time. And soon well universalize the technology for human health too. Our mission is to end bacterial disease.

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery. Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who dont respond to available treatments. The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who dont respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.

Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.

TimelyAI is building a Marketing Saas for Time-based Businesses. “The idea is to solve the most burning need of our customers- Growing their clientele at an affordable price and being able to build lasting relationships with them for repeat business and referrals.” "Coming soon with something extremely crazy!"

A network for entrepreneurs building in stealth. Submit your information here so investors can find you: harmonic.ai/get-discovered

CCX empowers you to plan, negotiate, and administer deals on your terms, with a simple and configurable infrastructure. Our proven technology delivers your strategy, and better outcomes.

Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development.